

IDO Pathway and Cancer

Key Immuno-Oncology Target

- ▶ IDO (indoleamine 2,3-dioxygenase) is an intracellular enzyme that regulates immune responses and when the pathway is active, results in an immuno-suppressive phenotype rather than an activated anti-tumor phenotype¹
- ▶ Tumors hijack the IDO pathway, a normal part of the immune system, to facilitate immune escape²
- ▶ Used in combination with other cancer therapies, IDO pathway inhibitors are being evaluated in multiple tumor types to potentially improve outcomes for patients with cancer

¹ Mertz, R. *Oncoimmunology*. 2012;1(9):1460-1468.

² Johnson TS. *Immunol Invest*. 2012;41(6-7):765-797.

Targeting the IDO Pathway Two Strategies for Inhibition

- ▶ Indoximod
 - Acts directly on immune cells to reverse IDO pathway mediated suppression
- ▶ Navoximod (GDC-0919)
 - Direct IDO enzymatic inhibitor, blocks tryptophan metabolism^{1,2}
- ▶ Available data indicate similar activity with both approaches³

¹ Mautino, M. *AACR* 2013. Abstract 491.

² Jochems, C. *Oncotarget*. 2016;7(25):37762-37772.

³ Mautino, M. *AACR* 2013. Abstract 5023.

